Supernus Pharmaceuticals (SUPN) Share-based Compensation Growth (3y) (2014 - 2026)
Supernus Pharmaceuticals (SUPN) Share-based Compensation Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 12.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.38% |
| Mar 31, 2026 | 20.54% |
| Dec 31, 2025 | 20.25% |
| Sep 30, 2025 | 2.14% |
| Jun 30, 2025 | -37.12% |
| Mar 31, 2025 | 398.32% |
| Dec 31, 2024 | 36.62% |
| Sep 30, 2024 | 23.98% |
| Jun 30, 2024 | 21.60% |
| Mar 31, 2024 | -15.86% |
| Sep 30, 2023 | -34.51% |
| Mar 31, 2023 | -13.28% |
| Dec 31, 2022 | 66.07% |
| Sep 30, 2022 | -42.07% |
| Jun 30, 2022 | -64.17% |
| Mar 31, 2022 | -79.82% |
| Dec 31, 2021 | -87.94% |
| Sep 30, 2021 | 15.75% |
| Jun 30, 2021 | 21.30% |
| Mar 31, 2021 | 18.38% |